HRP20201021T1 - Modificirane stanice domaćini i njihova upotreba - Google Patents
Modificirane stanice domaćini i njihova upotreba Download PDFInfo
- Publication number
- HRP20201021T1 HRP20201021T1 HRP20201021TT HRP20201021T HRP20201021T1 HR P20201021 T1 HRP20201021 T1 HR P20201021T1 HR P20201021T T HRP20201021T T HR P20201021TT HR P20201021 T HRP20201021 T HR P20201021T HR P20201021 T1 HRP20201021 T1 HR P20201021T1
- Authority
- HR
- Croatia
- Prior art keywords
- nucleic acid
- bioconjugate
- antigen
- host cell
- bacterium
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 241000589516 Pseudomonas Species 0.000 claims 5
- 241000894006 Bacteria Species 0.000 claims 4
- 102000014914 Carrier Proteins Human genes 0.000 claims 4
- 108010078791 Carrier Proteins Proteins 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 108091035707 Consensus sequence Proteins 0.000 claims 2
- 108700023372 Glycosyltransferases Proteins 0.000 claims 2
- 102000051366 Glycosyltransferases Human genes 0.000 claims 2
- 230000004988 N-glycosylation Effects 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 108010089072 Dolichyl-diphosphooligosaccharide-protein glycotransferase Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 102000006933 Hydroxymethyl and Formyl Transferases Human genes 0.000 claims 1
- 108010072462 Hydroxymethyl and Formyl Transferases Proteins 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000014616 translation Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Claims (11)
1. Stanica domaćin, naznačena time što sadrži:
i. nukleinsku kiselinu koja kodira glikoziltransferazu dobivenu iz grozda rfb iz bakterije iz roda Pseudomonas;
ii. nukleinsku kiselinu koja kodira enzim formiltransferazu, gdje navedena nukleinska kiselina kodira protein koji je otprilike ili najmanje 80%, 85%, 90%, 95%, 96%, 97%, 98%, ili 99% istovjetan ili homologan u odnosu na SEQ ID NO:2, ili što navedena nukleinska kiselina kodira SEQ ID NO:2;
iii. nukleinsku kiselinu koja kodira oligosaharil-transferazu; i
iv. nukleinsku kiselinu koja kodira protein nosač koji sadrži N-glikozilacijski konsenzusni slijed D/E-X-N-X-S/T, gdje je X bilo koja aminokiselina osim prolina.
2. Stanica domaćin u skladu s patentnim zahtjevom 1, naznačena time što dodatno sadrži nukleinsku kiselinu koja kodira polimerazu wzy, gdje navedena nukleinska kiselina kodira protein koji je otprilike ili najmanje 80%, 85%, 90%, 95%, 96%, 97%, 98%, ili 99% istovjetan ili homologan u odnosu na SEQ ID NO:3, ili što navedena nukleinska kiselina kodira SEQ ID NO:3.
3. Stanica domaćin u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačena time što se glikoziltransferazu dobiva iz grozda rfb iz bakterije Pseudomonas aeruginosa serotip 6.
4. Stanica domaćin u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačena time što je navedena stanica domaćin E. coli.
5. Postupak dobivanja biokonjugata koji sadrži antigen iz bakterije iz roda Pseudomonas vezan na protein nosač, naznačen time što se navedeni postupak sastoji u uzgoju stanice domaćina u skladu s bilo kojim od patentnih zahtjeva 1-4 u uvjetima pogodnim za proizvodnju proteina.
6. Biokonjugat dobiven postupkom u skladu s patentnim zahtjevom 5, naznačen time što navedeni biokonjugat sadrži antigen iz bakterije Pseudomonas vezan na protein nosač.
7. Biokonjugat, naznačen time što sadrži serotipni antigen O6 iz bakterije Pseudomonas aeruginosa konjugiran s proteinom nosačem preko ostatka N u najmanje jednom N-glikozilacijskom konsenzusnom slijedu D/E-X-N-X-S/T, gdje je X bilo koja aminokiselina osim prolina na kojem je formiliran antigen O6.
8. Biokonjugat u skladu s patentnim zahtjevom 7, naznačen time što antigen O6 sadrži formilnu skupinu vezanu na najmanje 1 ostatak GalNFmA.
9. Biokonjugat u skladu s patentnim zahtjevom 8, naznačen time što je formilirano najmanje 10, 20, 30, 40, 50, 60, 70, 80, 90, 95 ili 100% ponavljanih jedinica antigena O.
10. Biokonjugat u skladu s bilo kojim od patentnih zahtjeva 8-9, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju bolesti koju uzrokuje zaraza bakterijama iz roda Pseudomonas kod ljudskog subjekta.
11. Biokonjugat u skladu s bilo kojim od patentnih zahtjeva 8-9, naznačen time što je namijenjen upotrebi u proizvodnji medikamenta za liječenje ili sprječavanje bolesti koju uzrokuju bakterije iz roda Pseudomonas kod ljudskog subjekta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461980988P | 2014-04-17 | 2014-04-17 | |
| PCT/EP2014/071898 WO2015158403A1 (en) | 2014-04-17 | 2014-10-13 | Modified host cells and uses thereof |
| EP14784210.8A EP3131577B1 (en) | 2014-04-17 | 2014-10-13 | Modified host cells and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201021T1 true HRP20201021T1 (hr) | 2020-10-16 |
Family
ID=51726491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201021TT HRP20201021T1 (hr) | 2014-04-17 | 2020-06-29 | Modificirane stanice domaćini i njihova upotreba |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20170035900A1 (hr) |
| EP (2) | EP3131577B1 (hr) |
| JP (2) | JP6682451B2 (hr) |
| CN (1) | CN106794237B (hr) |
| BR (1) | BR112016023688B1 (hr) |
| CA (1) | CA2945542C (hr) |
| CY (1) | CY1123403T1 (hr) |
| DK (1) | DK3131577T3 (hr) |
| ES (2) | ES2805000T3 (hr) |
| HR (1) | HRP20201021T1 (hr) |
| HU (1) | HUE049806T2 (hr) |
| LT (1) | LT3131577T (hr) |
| MX (1) | MX378857B (hr) |
| PL (1) | PL3131577T3 (hr) |
| PT (1) | PT3131577T (hr) |
| SI (1) | SI3131577T1 (hr) |
| WO (1) | WO2015158403A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| CN105732818B (zh) * | 2016-03-02 | 2019-06-07 | 中国人民解放军第三军医大学 | 一种铜绿假单胞菌重组蛋白pop及其制备方法和应用 |
| AU2018290298B2 (en) * | 2017-06-23 | 2024-03-28 | Affinivax, Inc. | Immunogenic compositions |
| US11993778B2 (en) | 2017-10-25 | 2024-05-28 | Pivot Bio, Inc. | Methods and compositions for improving engineered microbes that fix nitrogen |
| JP2021500907A (ja) | 2017-10-25 | 2021-01-14 | ピボット バイオ， インコーポレイテッド | 植物の形質の改良を目的とした窒素固定のための遺伝子標的 |
| MX2020014295A (es) * | 2018-06-27 | 2021-05-27 | Pivot Bio Inc | Remodelacion microbiana guiada, una plataforma para la mejora racional de especies microbianas para la agricultura. |
| EA202192390A1 (ru) | 2019-03-18 | 2021-12-03 | Янссен Фармасьютикалз, Инк. | Биоконъюгаты полисахаридных о-антигенов e.coli, способы их получения и способы их применения |
| KR102574882B1 (ko) | 2019-03-18 | 2023-09-04 | 얀센 파마슈티칼즈, 인코포레이티드 | 대장균 o-항원 다당류의 바이오컨쥬게이트의 생성 방법, 이의 조성물 및 이의 사용 방법 |
| KR20220141834A (ko) * | 2020-03-12 | 2022-10-20 | 말시스보 아게 | 글리코엔지니어링된 박테리아를 포함하는 백신 |
| TW202227128A (zh) | 2020-09-17 | 2022-07-16 | 美商詹森藥物公司 | 多價疫苗組成物及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DK1481057T3 (da) | 2002-03-07 | 2006-05-15 | Eidgenoess Tech Hochschule | System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært |
| DK1888761T3 (da) * | 2005-05-11 | 2010-11-01 | Eth Zuerich | Rekombinante N-glycosylerede proteiner fra prokaryote celler |
| ES2376492T3 (es) | 2006-03-23 | 2012-03-14 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores. |
| ES2388556T3 (es) | 2006-03-23 | 2012-10-16 | Novartis Ag | Compuestos inmunopotenciadores |
| SI2257307T1 (sl) * | 2008-02-20 | 2018-09-28 | Glaxosmithkline Biologicals S.A. | Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic |
| PT2501406T (pt) * | 2009-11-19 | 2018-02-21 | Glaxosmithkline Biologicals Sa | Sistema de biossíntese que produz polissacáridos imunogénicos em células procariotas |
| KR101916290B1 (ko) * | 2010-05-06 | 2018-11-09 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 캡슐형 그람-양성 세균 생체접합체 백신 |
| JP2014526449A (ja) * | 2011-09-06 | 2014-10-06 | グリコヴァキシン アーゲー | 原核細胞において製造されるバイオコンジュゲートワクチン |
| SG11201501391YA (en) * | 2012-09-10 | 2015-03-30 | Glycovaxyn Ag | Bioconjugates comprising modified antigens and uses thereof |
| TR201904022T4 (tr) * | 2012-10-12 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Konakçı hücre modifikasyon yöntemleri. |
| JP6412875B2 (ja) * | 2012-11-07 | 2018-10-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 酵素的コンジュゲート化による大腸菌での組み換えワクチンの製造 |
| EP3055416B1 (en) * | 2013-10-11 | 2020-01-22 | GlaxoSmithKline Biologicals S.A. | Methods of host cell modification |
-
2014
- 2014-10-13 CN CN201480079804.3A patent/CN106794237B/zh active Active
- 2014-10-13 JP JP2016562754A patent/JP6682451B2/ja active Active
- 2014-10-13 ES ES14784210T patent/ES2805000T3/es active Active
- 2014-10-13 WO PCT/EP2014/071898 patent/WO2015158403A1/en active Application Filing
- 2014-10-13 EP EP14784210.8A patent/EP3131577B1/en active Active
- 2014-10-13 LT LTEP14784210.8T patent/LT3131577T/lt unknown
- 2014-10-13 PL PL14784210T patent/PL3131577T3/pl unknown
- 2014-10-13 SI SI201431611T patent/SI3131577T1/sl unknown
- 2014-10-13 EP EP20170090.3A patent/EP3711776B1/en active Active
- 2014-10-13 PT PT147842108T patent/PT3131577T/pt unknown
- 2014-10-13 ES ES20170090T patent/ES2939470T3/es active Active
- 2014-10-13 BR BR112016023688-2A patent/BR112016023688B1/pt active IP Right Grant
- 2014-10-13 US US15/304,557 patent/US20170035900A1/en not_active Abandoned
- 2014-10-13 CA CA2945542A patent/CA2945542C/en active Active
- 2014-10-13 MX MX2016013631A patent/MX378857B/es unknown
- 2014-10-13 HU HUE14784210A patent/HUE049806T2/hu unknown
- 2014-10-13 DK DK14784210.8T patent/DK3131577T3/da active
-
2020
- 2020-03-25 JP JP2020053544A patent/JP2020114232A/ja active Pending
- 2020-06-29 HR HRP20201021TT patent/HRP20201021T1/hr unknown
- 2020-07-09 CY CY20201100633T patent/CY1123403T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3131577T3 (pl) | 2020-10-19 |
| MX2016013631A (es) | 2017-02-28 |
| LT3131577T (lt) | 2020-07-27 |
| ES2805000T3 (es) | 2021-02-10 |
| JP6682451B2 (ja) | 2020-04-15 |
| WO2015158403A1 (en) | 2015-10-22 |
| PT3131577T (pt) | 2020-07-17 |
| CA2945542C (en) | 2024-03-05 |
| CA2945542A1 (en) | 2015-10-22 |
| BR112016023688A2 (pt) | 2018-01-30 |
| CN106794237B (zh) | 2022-04-12 |
| ES2939470T3 (es) | 2023-04-24 |
| SI3131577T1 (sl) | 2020-08-31 |
| JP2020114232A (ja) | 2020-07-30 |
| EP3711776A1 (en) | 2020-09-23 |
| CN106794237A (zh) | 2017-05-31 |
| BR112016023688B1 (pt) | 2024-01-09 |
| DK3131577T3 (da) | 2020-07-13 |
| CY1123403T1 (el) | 2022-03-24 |
| HUE049806T2 (hu) | 2020-10-28 |
| EP3131577A1 (en) | 2017-02-22 |
| MX378857B (es) | 2025-03-10 |
| JP2017513480A (ja) | 2017-06-01 |
| EP3711776B1 (en) | 2023-01-11 |
| US20170035900A1 (en) | 2017-02-09 |
| EP3131577B1 (en) | 2020-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201021T1 (hr) | Modificirane stanice domaćini i njihova upotreba | |
| HRP20211594T1 (hr) | Anti-pd1 protutijela i načini uporabe | |
| FI3110441T3 (fi) | Uusi polysakkaridi ja sen käyttöjä | |
| BR112014014526A8 (pt) | Cultura biologicamente pura, composição, método para tratar sementes, e, sementes | |
| MX2022002665A (es) | Composiciones que comprenden celulas recombinantes de bacillus y otro agente de control biologico. | |
| CO6880050A2 (es) | Composiciones y metodos para controlar la fusariosis | |
| JP2018520654A5 (hr) | ||
| Neamah | Molecular Detection of virulence factor genes in Pseudomonas aeruginosa isolated from human and animals in Diwaniya province | |
| BRPI1008740A8 (pt) | Proteínas pesticidas e métodos para seu uso. | |
| GT201200058A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| BR112015023424A2 (pt) | construto de expressão engenheirado, método para aprimoramento de produção de rna ou proteína, vetor, célula, hospedeira bacteriana, sistema de cultura de célula para síntese in vivo de dsrna, composição e método para controlar uma infestação de pragas de invertebrados ou para inibir a propagação de uma doença viral em uma população de plantas, e terminador transcricional | |
| BR112014001909A2 (pt) | gene da toxina axmi270 e métodos para a sua utilização | |
| DK2566507T3 (da) | Biokonjugatvacciner med kapselformige grampositive bakterier | |
| BR112014022166A2 (pt) | gene da delta-endotoxina axmi345 e métodos para a sua utilização | |
| UA115235C2 (uk) | Ген токсину axmi335 bacillus thuringiensis та спосіб його застосування | |
| BR112014001978A2 (pt) | proteínas variantes axmi205 e métodos para a utilização das mesmas | |
| WO2013042900A3 (en) | Novel strain bacillus vallismortis bso7m capable of promoting growth of plant and confering cold resistance on plant and microbial formulation comprising the same | |
| HRP20241279T1 (hr) | Pripravak koji sadrži probiotike koji prekomjerno eksprimiraju protein clpb za uporabu u liječenju pretilosti | |
| RU2015114955A (ru) | Способ получения L-изолейцина с использованием бактерии семейства Enterobacteriaceae, в которой сверхэкспрессирован ген cycA | |
| RU2017142878A (ru) | Микроорганизм рода Escherichia, обладающий продуктивностью по L-триптофану, и способ получения L-триптофана с его использованием | |
| RU2017141773A (ru) | Микроорганизм рода Escherichia, продуцирующий L-триптофан, и способ получения L-триптофана с его использованием | |
| HRP20191864T1 (hr) | Imunogeni pripravci protiv bakterije clostridium difficile | |
| RU2016145258A (ru) | Микроорганизм, обладающий улучшенным уровнем внутриклеточной энергии, и способ продуцирования l-аминокислоты с его помощью | |
| JP2016086711A5 (hr) | ||
| JP2015529455A5 (hr) |